Koch Kevin's Form 4 filing
Edgewise Therapeutics, Inc. (EWTX) · filed Aug 14, 2026
- Accession no.
- 0001185829-26-000001
- Filed
- Aug 14, 2026, 4:52 PM ET
- Trade date
- Aug 12, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions and 4 derivative transactions. Open-market sales total $785.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Koch KevinCIK 0001185829 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | Common Stock | MOption exerciseAcquired | +17,969 | $0.00 | $0 | 48,584 | Direct | |
| Aug 12, 2026 | Common Stock | MOption exerciseAcquired | +21,875 | $0.00 | $0 | 70,459 | Direct | |
| Aug 12, 2026 | Common Stock | SSaleDisposed | −8,782 | $43.64F2 | −$383,253.51 | 61,677 | Direct | |
| Aug 12, 2026 | Common Stock | SSaleDisposed | −8,276 | $43.66F3 | −$361,315.26 | 53,401 | Direct | |
| Aug 12, 2026 | Common Stock | SSaleDisposed | −913 | $44.33F4 | −$40,473.29 | 52,488 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | Common Stock | MOption exerciseDisposed | −17,969 | $0.00 | $0 | 35,938 | Direct | |
| Aug 12, 2026 | Common Stock | MOption exerciseDisposed | −21,875 | $0.00 | $0 | 65,625 | Direct | |
| Aug 12, 2026 | Common Stock | AGrant or awardAcquired | +100,000 | $0.00 | $0 | 100,000 | Direct | |
| Aug 12, 2026 | Common Stock | AGrant or awardAcquired | +200,000 | $0.00 | $0 | 200,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $ 43.26 to $44.10, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.37 to $44.27, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.33 to $44.33, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.